Allianz Asset Management GmbH Boosts Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Allianz Asset Management GmbH lifted its stake in Bio-Rad Laboratories, Inc. (NYSE:BIOGet Rating) by 56.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 58,158 shares of the medical research company’s stock after purchasing an additional 20,905 shares during the period. Allianz Asset Management GmbH owned 0.19% of Bio-Rad Laboratories worth $43,943,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the company. FMR LLC increased its stake in shares of Bio-Rad Laboratories by 12.7% in the 1st quarter. FMR LLC now owns 182,762 shares of the medical research company’s stock worth $55,867,000 after acquiring an additional 20,560 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund increased its stake in shares of Bio-Rad Laboratories by 1,528.2% in the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,384 shares of the medical research company’s stock worth $1,032,000 after acquiring an additional 1,299 shares in the last quarter. Creative Planning increased its stake in shares of Bio-Rad Laboratories by 2.1% in the 3rd quarter. Creative Planning now owns 1,080 shares of the medical research company’s stock worth $806,000 after acquiring an additional 22 shares in the last quarter. Rafferty Asset Management LLC increased its stake in shares of Bio-Rad Laboratories by 53.6% in the 3rd quarter. Rafferty Asset Management LLC now owns 685 shares of the medical research company’s stock worth $511,000 after acquiring an additional 239 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in shares of Bio-Rad Laboratories by 25.0% in the 3rd quarter. Goldman Sachs Group Inc. now owns 78,786 shares of the medical research company’s stock worth $58,770,000 after acquiring an additional 15,747 shares in the last quarter. 63.66% of the stock is owned by hedge funds and other institutional investors.

BIO opened at $522.20 on Friday. The company has a current ratio of 5.10, a quick ratio of 4.16 and a debt-to-equity ratio of 0.12. The company has a market cap of $15.63 billion, a price-to-earnings ratio of -107.01 and a beta of 0.93. The company’s 50 day moving average is $542.61 and its 200 day moving average is $628.67. Bio-Rad Laboratories, Inc. has a 12-month low of $468.86 and a 12-month high of $832.70.

Bio-Rad Laboratories (NYSE:BIOGet Rating) last posted its quarterly earnings data on Thursday, April 28th. The medical research company reported $4.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.80 by $2.14. The company had revenue of $700.10 million for the quarter, compared to the consensus estimate of $678.00 million. Bio-Rad Laboratories had a negative net margin of 3.49% and a positive return on equity of 3.66%. The firm’s revenue was down 3.7% compared to the same quarter last year. During the same quarter last year, the firm posted $5.21 earnings per share. As a group, analysts predict that Bio-Rad Laboratories, Inc. will post 14.2 EPS for the current fiscal year.

BIO has been the subject of a number of analyst reports. Citigroup reduced their price objective on shares of Bio-Rad Laboratories from $800.00 to $750.00 in a research note on Monday, May 2nd. StockNews.com initiated coverage on shares of Bio-Rad Laboratories in a research note on Thursday, March 31st. They set a “hold” rating for the company. Jefferies Financial Group restated a “buy” rating and set a $700.00 price objective on shares of Bio-Rad Laboratories in a research note on Friday, April 29th. TheStreet downgraded shares of Bio-Rad Laboratories from a “b-” rating to a “c+” rating in a report on Thursday, April 28th. Finally, Zacks Investment Research raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating and set a $526.00 price target on the stock in a report on Wednesday, May 4th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $726.50.

About Bio-Rad Laboratories (Get Rating)

Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.

Recommended Stories

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIOGet Rating).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.